第一代Mitroflow生物瓣主动脉瓣置换的十年结果:早期退化是结构还是技术问题?
本研究回顾性分析510例(467例完整随访)使用第一代Mitroflow主动脉生物瓣行主动脉瓣置换的患者,中位随访6.6年。10年生存率33.3%,结构性瓣膜退化(SVD)累积发生率6.2%。仅年龄<75岁 tended to 影响SVD晚期风险(HR 0.50,95%CI 0.23-1.08,P=0.08)。数据不支持该瓣膜在>75岁患者中早期加速结构退化的担忧,认为限制小尺寸瓣膜使用可减少患者-瓣膜不匹配。
要点
- 10年SVD累积发生率6.2%,早期退化担忧未获支持。
- 年龄<75岁 tended to 增加SVD风险(HR 0.50,P=0.08)。
- 避免患者-瓣膜不匹配可能降低早期SVD风险。
核心结论
- 数据不支持第一代Mitroflow生物瓣在>75岁患者中早期加速结构退化的担忧。
- 限制小尺寸瓣膜使用并采用正确植入技术可减少患者-瓣膜不匹配,可能是降低早期SVD风险的主要因素。
研究设计与样本
- 回顾性队列研究,2003年6月至2012年5月共510例使用Mitroflow瓣膜行主动脉瓣置换,其中467例完整临床随访纳入分析。
- 中位随访6.6年(四分位距4.4),累计2375患者年。
- SVD分析采用累积发生率函数和竞争风险Cox回归。
主要发现
- 平均年龄76.4±6.1岁;瓣膜尺寸23-25占70.4%,19-21仅占19.2%,89.1%避免了患者-瓣膜不匹配。
- 1年、5年、10年生存率分别为86.2%、67.3%、33.3%。
- 以死亡为竞争风险,SVD累积发生率1年、5年、10年分别为0%、0.7%、6.2%。
- 仅年龄<75岁 tended to 影响SVD晚期风险(HR 0.50,95%CI 0.23-1.08,P=0.08)。
临床怎么用
- 对于>75岁主动脉瓣置换患者,第一代Mitroflow生物瓣的早期结构退化风险未显著增加。
- 术中应避免使用过小尺寸瓣膜并采用正确植入技术,以减少患者-瓣膜不匹配。
局限性
- 单中心经验,瓣膜选择存在选择偏倚。
- 年龄<75岁对SVD的影响仅为趋势(P=0.08),未达统计学显著性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Concerns have been raised about the durability of the first-generation Mitroflow aortic bioprosthesis (model 12 A-LX) due to the lack of anticalcification treatment. This study reflects a 10-year experience with this prosthesis for aortic valve replacement. METHODS: From June 2003 to May 2012, the Mitroflow prosthesis was used for aortic valve replacement in 510 patients, of whom only 467 with complete clinical follow-up were included for analysis. Study end-points were survival and incidence of structural valve degeneration (SVD). Analysis of SVD was based on cumulative incidence function and competing-risk Cox regression. RESULTS: The mean patient age was 76.4 ± 6.1 years. Valve sizes from 23 to 25 were used in 70.4%, whereas sizes from 19 to 21 were used in only 19.2%, thereby avoiding patient-prosthesis mismatch in 89.1%. Within a median follow-up time of 6.6 years (interquartile range 4.4), a cumulative 2375 patient-years, the survival rate was 86.2%, 67.3% and 33.3% at 1, 5 and 10 years, respectively. The cumulative incidence of SVD, with death as a competing risk, was 0%, 0.7% and 6.2% at 1, 5 and 10 years, respectively. Only age <75 years tended to affect the late hazard of SVD (hazard ratio 0.50, 95% confidence interval 0.23-1.08, P = 0.08), regardless of valve-specific issues. CONCLUSIONS: The data do not support the concerns about early accelerated structural degeneration of the first-generation Mitroflow bioprosthesis used for aortic valve replacement in patients older than 75 years. We postulate that limiting the number of small prostheses using a proper implantation technique has enhanced the reduction in risk of significant patient-prosthesis mismatch as the main determinant of early SVD.
引用
- Lootens L, Verbeke J, Martens T, et al. Ten-year results of aortic valve replacement with first-generation Mitroflow bioprosthesis: is early degeneration a structural or a technical issue? Eur J Cardiothorac Surg. 2017. PMID: 28430883. doi:10.1093/ejcts/ezx117
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。